{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:31:46Z","timestamp":1791117106862,"version":"4.1.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/rhu.0b013e31823b0ca5","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T07:21:59Z","timestamp":1322637719000},"page":"429-431","source":"Crossref","is-referenced-by-count":5,"title":["Antiphospholipid Antibodies in Malignancy"],"prefix":"10.1097","volume":"17","author":[{"given":"Nayab","family":"Mahaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela E.","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210207","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":". International consensus statement on an update of the classification criteria for the definite antiphospholipid syndrome (APS).","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R2-5-20210207","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/jaut.2000.0404","article-title":"Antiphospholipid antibodies, malignancies, and paraproteinemias.","volume":"15","author":"Asherson","year":"2000","journal-title":"J Autoimmun"},{"key":"R3-5-20210207","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.hoc.2007.10.004","article-title":"Antiphospholipid antibodies and malignancy.","volume":"22","author":"Pham","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-5-20210207","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.autrev.2009.04.001","article-title":"Antiphospholipid antibodies and malignancies.","volume":"9","author":"Tincani","year":"2010","journal-title":"Autoimmun Rev"},{"key":"R6-5-20210207","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1995.353","article-title":". Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy.","volume":"72","author":"Zuckerman","year":"1995","journal-title":"Br J Cancer"},{"key":"R7-5-20210207","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1191\/0961203303lu328oa","article-title":". High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis.","volume":"12","author":"Yoon","year":"2003","journal-title":"Lupus"},{"key":"R8-5-20210207","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.autrev.2010.10.006","article-title":". Solid cancer, antiphospholipid antibodies, and venous thromboembolism.","volume":"10","author":"Font","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R9-5-20210207","first-page":"175","article-title":". A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) study.","volume":"24","author":"Schved","year":"1994","journal-title":"Haemostasis"},{"key":"R10-5-20210207","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.thj.6200377","article-title":". Antiphospholipid antibodies in lymphoma: prevalence and clinical significance.","volume":"5","author":"Pusterla","year":"2004","journal-title":"Hematol J"},{"key":"R11-5-20210207","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s10067-005-0181-2","article-title":"Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies.","volume":"25","author":"Miesbach","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R12-5-20210207","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1034\/j.1600-0609.2002.01526.x","article-title":". Prevalence and clinical significance of anticardiolipin and anti-B2-glycoprotein-I antibodies in patients with non-Hodgkins lymphoma.","volume":"68","author":"Genvresse","year":"2002","journal-title":"Eur J Haematol"},{"key":"R13-5-20210207","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11739-009-0316-6","article-title":". Presence of low titre of antiphospholipid antibodies in cancer patients: a prospective study.","volume":"4","author":"Bazzan","year":"2009","journal-title":"Intern Emerg Med"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RHU.0b013e31823b0ca5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:25:29Z","timestamp":1786047929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00124743-201112000-00005"}},"subtitle":["Are These Pathogenic or Epiphenomena?"],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31823b0ca5","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}